Europe Glucagon Market

Europe Glucagon Market Size

The size of the Europe glucagon market was valued at USD 199.12 million in 2025. This market is expected to grow at a CAGR of 6.38% from 2026 to 2034 and be worth USD 347 million by 2034 from USD 211.82 million in 2026.

Glucagon is a natural peptide hormone produced by the alpha cells of the pancreas that works as the primary "counter-hormone" to insulin. Unlike insulin, which lowers blood glucose, glucagon stimulates hepatic glycogenolysis to rapidly elevate blood sugar levels during acute neuroglycopenic episodes. In Europe, glucagon is available in lyophilized powder form requiring reconstitution, as well as in newer ready-to-use liquid auto injectors and nasal powders approved under the European Medicines Agency’s centralized procedure. The clinical relevance of this market is underscored by the rising prevalence of insulin-dependent diabetes and the persistent risk of hypoglycemia despite advances in glucose monitoring. The International Diabetes Federation reports that a significant and growing number of adults in the European region are living with diabetes, with a substantial portion requiring insulin therapy. Furthermore, studies indicate that a considerable proportion of individuals with type 1 diabetes experience serious, low blood sugar events annually that necessitate assistance from others. This unmet need for rapid, accessible rescue therapy defines the functional necessity of glucagon across European healthcare systems.

MARKET DRIVERS

Rising Prevalence of Insulin-Treated Diabetes and Hypoglycemia Incidence

The expanding population of insulin-dependent diabetics across the region directly fuels demand for glucagon as a life-saving rescue medication, which acts as a major accelerator of the Europe glucagon market. The International Diabetes Federation reports a rapid rise in the number of people living with type 1 diabetes across Europe, with a significant portion of these cases affecting adults, while a growing number of individuals with type 2 diabetes require insulin therapy as their condition progresses. Despite the increased uptake of continuous glucose monitoring technology, a notable portion of patients with insulin-treated diabetes continues to experience severe, debilitating hypoglycemic events that require assistance. National health agencies reinforce preparedness. The National Institute for Health and Care Excellence (NICE) recommends that individuals with insulin-treated diabetes at high risk of severe hypoglycemia should be prescribed emergency glucagon, along with appropriate training on how to use it. Similarly, Germany’s Federal Joint Committee requires glucagon prescription at insulin initiation. This clinical imperative, backed by guideline enforcement, ensures consistent and growing demand for accessible glucagon formulations across primary care and emergency settings throughout Europe.

Regulatory Endorsement and Reimbursement of Next Generation Glucagon Delivery Systems

The European Medicines Agency’s approval and national reimbursement of user-friendly glucagon delivery platforms have significantly broadened real-world accessibility and adoption, which contributes to the expansion of the Europe glucagon market. Traditional lyophilized kits required multi-step reconstitution, a barrier during emergencies, whereas newer options like ready-to-use auto injectors and nasal powders enable administration by laypersons. The European Medicines Agency authorized multiple novel glucagon products, including nasal powder and liquid-stable, ready-to-use formulations, between 2019 and 2024 to replace traditional emergency kits. Critically, countries like France, Germany, and Sweden now include these innovations in public drug formularies with full or partial reimbursement. Nasal glucagon prescriptions in France grew significantly following its integration into the national long-term illness coverage scheme. This regulatory and financial support transforms glucagon from a theoretically available rescue tool into a practically utilized intervention, driving market expansion beyond historical limitations of usability and training requirements.

MARKET RESTRAINTS

High Cost of Next Generation Formulations Limits Broad Accessibility

The premium pricing of ready-to-use glucagon products restricts widespread adoption, particularly in cost-conscious healthcare systems and among uninsured populations, and thereby inhibits the growth of the Europe glucagon market. Modern, ready-to-use glucagon products, such as nasal sprays and auto-injectors, are significantly more expensive at the retail level compared to traditional reconstitution kits, leading to a large cost disparity between the two types of emergency, severe hypoglycemia treatments. Reimbursement coverage in Western Europe contrasts with the prohibitive out-of-pocket expenses prevalent in Eastern and Southern member states. In several European markets with lower income levels, such as Romania and Greece, a large portion of patients face financial barriers to accessing unsubsidized next-generation glucagon products, making them less accessible than conventional, subsidized, older-generation kits. Even in Germany, statutory insurers impose quantity limits, forcing families to ration or revert to older kits. This economic barrier contradicts public health goals of universal hypoglycemia preparedness and perpetuates disparities in emergency care access across socioeconomic and geographic lines, constraining the full potential of advanced glucagon technologies in the European market.

Low Awareness and Underutilization Among At-Risk Populations

Persistent gaps in patient and caregiver education result in chronic underutilization of glucagon, regardless of formulation availability, which restrains the expansion of the Europe glucagon market. A European survey indicates that a minority of insulin-treated patients possess a current glucagon prescription, with a notably lower portion receiving practical, hands-on training for its application. Fear of injection complexity, misconceptions about side effects, and overconfidence in glucose monitoring contribute to this gap. Data indicate that a low proportion of young people in Italy with Type 1 diabetes regularly carry glucagon for emergency use. Schools and workplaces often lack trained personnel, further limiting real-world deployment. The lack of enforced educational protocols in diabetes care, contrary to EASD recommendations, restricts glucagon usage, stifling market demand despite significant clinical utility.

MARKET OPPORTUNITIES

Integration into Digital Diabetes Management Ecosystems

The convergence of glucagon with digital health platforms provides a transformative opportunity to enhance adherence preparedness and emergency response, which is predicted to boost the growth of the Europe glucagon market. Emerging smart pens and continuous glucose monitors can now detect hypoglycemia trends and send alerts to caregivers with instructions to administer glucagon. Medtronic is expanding its European digital health footprint by integrating glucose monitoring systems with smart mobile applications to streamline diabetes management and improve emergency response readiness. Similarly, Lilly’s partnership with Glooko enables automatic glucagon prescription reminders when hypoglycemia patterns are detected in uploaded data. European health organizations report a significant rise in the adoption of connected digital platforms among people requiring insulin, which facilitates more effective delivery of critical care and emergency treatments. The evolution of digital therapeutic reimbursement allows glucagon makers to embed products into closed-loop safety networks, transforming emergency care from a reactive stockpile into a proactive, data-driven system.

Expansion into Non-Emergency Indications, Including Diagnostic and Gastrointestinal Applications

Glucagon has an established role as a smooth muscle relaxant in radiological and endoscopic procedures, which paves the way for potential prospects for the Europe glucagon market. This offers a stable secondary market that buffers against fluctuations in diabetes care. During upper GI imaging or colonoscopy, intravenous glucagon temporarily inhibits peristalsis to improve visualization. Diagnostic procedures involving intestinal imaging in European hospitals frequently utilize intravenous pharmacological agents to reduce bowel motility, with the choice of medication often balanced between effective spasmolysis and individual patient cardiovascular risks. National formularies in Sweden, the Netherlands, and Austria list glucagon as first line for this indication, ensuring steady institutional demand. Moreover, emerging research explores glucagon co-agonists in obesity and metabolic syndrome, though still preclinical, these pathways could unlock future therapeutic extensions. This dual utility in emergency and diagnostic settings provides revenue diversification and reinforces glucagon’s indispensability in European clinical practice beyond diabetes alone.

MARKET CHALLENGES

Supply Chain Vulnerabilities and Manufacturing Complexity of Peptide Hormones

Glucagon’s status as a biologic peptide renders its production susceptible to raw material shortages, sterile processing constraints, and stringent quality control requirements, which lead to periodic supply disruptions and thereby slow down the growth of the Europe glucagon market. Unlike small molecule drugs, glucagon must be synthesized under aseptic conditions with rigorous endotoxin testing, limiting the number of qualified contract manufacturers in Europe. European regulatory bodies reported that GLP-1 receptor agonist medicines faced sustained supply disruptions across the region due to overwhelming demand and manufacturing, packaging, and supply capacity constraints. Supply chain issues, including manufacturing constraints at European sites, contributed to long-term shortages of critical diabetes and weight-loss medications, affecting availability in Benelux countries. These vulnerabilities are exacerbated by just-in-time inventory practices in hospitals and pharmacies. The market remains susceptible to logistics-driven shocks that jeopardize patient access and erode trust, a risk that will persist until regional production capacity is expanded, especially regarding next-gen liquid formulations.

Competition from Emerging Hypoglycemia Prevention Technologies

Advances in diabetes technology that reduce hypoglycemia incidence threaten to dampen long-term glucagon demand by addressing the root cause rather than the emergency consequence, which in turn constrains the expansion of the Europe glucagon market. Advanced hybrid closed-loop systems, which integrate continuous glucose monitoring with insulin delivery algorithms, are showing substantial improvements in overnight glucose control by drastically reducing the occurrence of nocturnal low blood sugar events. Automated insulin delivery systems are experiencing rapid adoption across Western Europe, with usage numbers expected to rise significantly over the coming years as this technology becomes standard care for insulin management. These technologies offer a significant reduction in hypoglycemia frequency, which may lower the perceived necessity for glucagon, even though they cannot eliminate risks associated with alcohol or exercise. Payers may question routine prescribing if severe events become rare, pressuring manufacturers to demonstrate value beyond episodic rescue. This technological displacement risk necessitates the strategic positioning of glucagon as an irreplaceable safety net even in the era of smart insulin delivery.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The injectable glucagon segment held the majority share of the Europe glucagon market in 2025. The supremacy of the injectable glucagon segment is driven by decades of clinical familiarity, established reimbursement pathways, and broad availability across hospital pharmacies and community settings. The traditional lyophilized powder formulation, requiring reconstitution with diluent before intramuscular or subcutaneous injection, remains the standard in most European healthcare systems due to its proven efficacy and lower cost. The European Medicines Agency indicates a shift in guidelines towards prioritizing ready-to-use, non-injectable options, although injectable glucagon remains a widely recognized, effective, and available, though often difficult-to-use, treatment for severe hypoglycemia. In countries like Germany and Italy, statutory health insurers fully reimburse multi-dose vials for diabetic patients, ensuring widespread access. Furthermore, emergency medical services and school nursing protocols across the EU are historically trained on injectable kits, creating institutional inertia. The European Resuscitation Council continues to reference injectable glucagon in its hypoglycemia management guidelines, reinforcing its clinical legitimacy. Despite usability challenges, this entrenched infrastructure, spanning prescribing habits, training programs, and supply chains, sustains injectable glucagon as the backbone of emergency diabetes care across Europe.

The nasal glucagon segment is predicted to witness the highest CAGR of 12.4% between 2026 and 2034 due to its ease of use, needle-free administration, and strong endorsement from patient advocacy groups and regulatory bodies. Unlike injectable kits that require multi-step preparation during high-stress emergencies, nasal glucagon, delivered as a single-dose powder via a pre-loaded device, can be administered by untrained caregivers in seconds. Following its initial approval by European health authorities, this needle-free emergency treatment has been increasingly incorporated into the standard care protocols of several Northern European nations. Clinical simulations indicate that caregivers find the nasal delivery method much easier to use correctly than traditional injection kits during high-stress medical emergencies. Reimbursement expansion further fuels adoption. Expanded coverage under France’s national health system has simplified access for patients with chronic conditions, resulting in a notable rise in the use of this treatment option. Integrating nasal glucagon into digital diabetes platforms is rapidly shifting this innovative, user-centric tool from niche to mainstream.

By Application Insights

The emergency kits segment was the largest segment in the Europe glucagon market by accounting for a substantial share in 2025. The prominence of the emergency kits segment is credited to glucagon’s primary role as a life-saving rescue medication for severe hypoglycemia in insulin-treated diabetic patients. National diabetes guidelines across Europe mandate that all individuals on intensive insulin therapy maintain an emergency glucagon kit at home, school, or workplace. According to the International Diabetes Federation, a significant number of Europeans with diabetes require insulin treatment, and a notable portion of those, particularly the elderly or those with Type 1 diabetes, experience severe hypoglycemic episodes that require external assistance. The European Society of Endocrinology emphasizes that timely glucagon administration prevents seizures, coma, and death, making it a non-negotiable component of diabetes safety planning. Public health initiatives reinforce this. The UK’s National Health Service distributes glucagon kits through structured education programs like DAFNE. Similarly, Germany’s Federal Joint Committee requires co-prescription of glucagon with insulin initiation. This universal clinical imperative, backed by policy education and reimbursement, ensures emergency kits remain the overwhelming driver of glucagon demand across the region.

The diagnostic & motility segment is estimated to register the fastest CAGR of 6.8% over the forecast period, owing to glucagon’s irreplaceable role as a spasmolytic agent in gastrointestinal imaging and endoscopic procedures. During upper GI series colonoscopies and MR enterography, glucagon is administered intravenously to temporarily inhibit smooth muscle contractions, enabling clearer visualization of mucosal surfaces. According to clinical literature supported by European gastrointestinal imaging guidelines, pharmacological spasmolysis remains a standard component in abdominal diagnostic imaging, with hyoscine butylbromide generally preferred over glucagon due to its rapid effect, reliability, and cost-effectiveness. National formularies in Sweden, the Netherlands, and Austria explicitly list glucagon as first line for this indication, ensuring consistent hospital procurement. Moreover, the rise of minimally invasive diagnostics, driven by cancer screening programs such as the EU’s Beating Cancer Plan, expands procedural volume. Unlike emergency use, which may decline with advanced diabetes tech, diagnostic demand remains stable and institutionally embedded, offering a resilient and growing secondary market for glucagon manufacturers.

COUNTRY-LEVEL ANALYSIS

Germany Glucagon Market Analysis

Germany led the Europe glucagon market by accounting for a 22.5% share in 2025. The dominance of the German market is driven by comprehensive healthcare coverage, high insulin utilization, and strict clinical protocols. According to German health data, the country faces a substantial and rising demand for diabetes care, driven by a high prevalence of diagnosed Type 2 diabetes, which affects millions of adults, and a significant, albeit much smaller, population living with Type 1 diabetes, with an increasing number of cases overall. The Federal Joint Committee mandates that glucagon be prescribed at insulin initiation and reimbursed without co-payment under statutory health insurance. Hospitals and emergency services maintain standardized protocols for glucagon use in hypoglycemia management, ensuring institutional familiarity. Additionally, Germany was among the first EU nations to include nasal glucagon in its national formulary, accelerating adoption of next-generation formats. This combination of epidemiological burden, regulatory enforcement, and early innovation uptake solidifies Germany’s leadership in the European glucagon landscape.

United Kingdom Glucagon Market Analysis

The United Kingdom was the next prominent country in the Europe glucagon market by capturing a 16.7% share in 2025. The growth of the UK market is propelled by its systematic integration of glucagon into national diabetes education and public health programs. NHS England supports structured education programs like DAFNE to empower adults with type 1 diabetes to manage insulin and prevent severe hypoglycemia, which includes education on glucagon use. The NHS centrally procures both injectable and nasal glucagon, ensuring a consistent supply across primary and secondary care. Following updated guidance, there is a growing trend in the UK towards recommending easy-to-administer nasal glucagon as a preferred option for caregivers, contributing to a rise in prescriptions for needle-free rescue medication. School nurse networks and ambulance services are also equipped with emergency kits, creating a multi-layer safety net. This coordinated approach, linking education procurement and policy, makes the UK a model for real-world glucagon accessibility and preparedness.

France Glucagon Market Analysis

France is also a key player in the Europe glucagon market by emerging as a pioneer in next-generation delivery adoption through progressive reimbursement policies. The French national health system updated its coverage policies to include ready-to-use nasal glucagon under the comprehensive long-term illness scheme, allowing full reimbursement for eligible insulin-dependent patients. Moreover, the improvement in reimbursement terms led to a significant increase in the adoption of nasal glucagon among patients, reflecting a shift away from traditional, more complex emergency treatments. France maintains a significant and growing prevalence of insulin-treated, chronic diabetes, contributing to a high burden on the national health insurance system. Hospital emergency departments routinely stock both injectable and nasal forms, and medical schools now teach dual administration techniques. This forward-looking combination of financial accessibility, clinical endorsement, and educational integration positions France as a key growth engine for innovative glucagon formats in Europe.

Sweden Glucagon Market Analysis

Sweden expanded steadily in the Europe glucagon market due to exceptional patient awareness and seamless integration into digital diabetes ecosystems. Swedish healthcare, recognized for its high standard of diabetes management, leads Europe in ensuring that patients with type 1 diabetes are equipped with modern emergency treatment, resulting in a very high proportion of individuals with access to a current, ready-to-use glucagon prescription. The national eHealth system allows automatic glucagon renewal alerts when insulin prescriptions are issued, reducing gaps in preparedness. Sweden was also among the first countries to adopt nasal glucagon in school and workplace emergency protocols following approval by the Medical Products Agency. Furthermore, partnerships between the Swedish Diabetes Association and tech companies embed glucagon instructions into CGM alert systems. This culture of proactive safety, supported by digital infrastructure and public health coordination, makes Sweden a benchmark for optimal glucagon utilization in a high-income welfare state.

Italy Glucagon Market Analysis

Italy is predicted to grow in the Europe glucagon market over the forecast period due to a substantial diabetic population, but uneven access across northern and southern regions. The number of individuals living with insulin-dependent diabetes in Italy is high, with significant regional variations in the management of the condition. In addition, the accessibility and prescribing of emergency diabetes medication (such as glucagon) show significant disparities across Italy, with northern regions generally exhibiting higher utilization rates compared to southern regions. Northern hospitals and pharmacies routinely stock both injectable and nasal forms, while southern areas face delays due to budget constraints and lower awareness. However, the National Diabetes Plan allocated dedicated funding to distribute emergency kits through primary care centers nationwide, aiming to reduce disparities. Despite these gaps, Italy’s large base of insulin users and recent policy reforms create significant latent demand, positioning it as a critical market for equitable glucagon access expansion in Southern Europe.

COMPETITIVE LANDSCAPE

The competition in the Europe glucagon market is defined by a strategic shift from legacy lyophilized products to next-generation ready-to-use delivery systems driven by usability and regulatory evolution. While established players like Novo Nordisk maintain dominance through entrenched hospital and pharmacy channels, newer entrants such as Xeris and Lilly compete on innovation, ease of use, and digital integration. Differentiation hinges on device design, stability, storage requirements, and compatibility with caregiver capabilities, rather than efficacy, which is clinically equivalent. Reimbursement status varies significantly across countries, creating a fragmented commercial landscape that demands localized market access strategies. As hypoglycemia prevention technologies advance, companies must also position glucagon as an irreplaceable safety net despite declining event frequency. The market rewards those who combine pharmaceutical reliability with human-centered design and systemic education to ensure real-world deployment during critical moments.

KEY MARKET PLAYERS

The leading companies operating in the Europe glucagon market include:

• Pzier Inc.
• Fresenius SE & Co. KGaA
• Eli Lilly & Co.
• Xeris Pharmaceuticals Ltd.
• Taj Pharmaceuticals
• Amgen Inc.
• Avalon Pharma Private Limited
• Bachem Holding AG
• Fujifilm Holdings
• Svar Life Science AB
• Novo Nordisk A/S

TOP PLAYERS IN THE MARKET

• Eli Lilly is a global leader in diabetes care with a strong presence in the Europe glucagon market through its innovative, ready-to-use liquid glucagon product Gvoke. The company pioneered the shift from lyophilized kits to user-friendly auto injectors and prefilled syringes that simplify emergency administration. Lilly actively collaborates with European diabetes associations to integrate glucagon training into structured education programs across the UK, Germany, and France. The integration of pharmacological and digital solutions enhances real-world effectiveness and reinforces Eli Lilly’s commitment to comprehensive diabetes safety in the Europe Glucagon Market.
• Novo Nordisk contributes significantly to the Europe glucagon market through its traditional lyophilized glucagon kits and ongoing development of next-generation rescue therapies. As a cornerstone of European diabetes care for decades, Novo Nordisk’s glucagon is widely stocked in hospitals, pharmacies, and schools across the region. The company leverages its extensive primary care network to ensure broad access and clinician familiarity with emergency protocols. Its public health-oriented approach strengthens its role as a trusted partner in hypoglycemia preparedness and sustains its relevance in the evolving Europe Glucagon Market.
• Xeris Biopharma has established a distinctive position in the Europe glucagon market with its room temperature stable liquid glucagon formulation Gvoke available as both an auto injector and prefilled syringe. Unlike traditional kits requiring refrigeration and reconstitution, Xeris’ technology enables immediate use without preparation, a critical advantage in emergencies. The company secured centralized marketing authorization from the European Medicines Agency and has since expanded reimbursement in key markets, including Sweden, the Netherlands, and France. Its focus on usability education and regulatory agility enhances Xeris Biopharma’s footprint in the Europe Glucagon Market.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the Europe glucagon market focus on developing user friendly ready to use formulations that eliminate reconstitution steps and enable administration by laypersons. They invest in digital health integrations such as mobile apps and CGM alerts to guide emergency response and improve adherence. Companies actively pursue national reimbursement approvals and collaborate with patient advocacy groups to drive prescription and awareness. Strategic partnerships with diabetes educator schools and emergency services expand real-world accessibility beyond clinical settings. Additionally, they conduct real-world evidence studies to demonstrate usability success rates and clinical outcomes that support regulatory and payer acceptance across diverse European healthcare systems.

MARKET SEGMENTATION

This research report on the Europe glucagon market has been segmented and sub-segmented into the following categories.

By Product Type

• Injectable

• Nasal

By Application

• Emergency Kits
• General Use
• Diagnostic & Motility
• Cardiogenic Shock
• Others

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe